GeoVax Labs, Inc.
(Public, OTC:GOVX) Watch this stockFind more results for
GOVX
Advertisement
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -179.15% | -128.11% |
| Operating margin | -180.08% | -130.62% |
| EBITD margin | - | -128.52% |
| Return on average assets | -208.03% | -118.33% |
| Return on average equity | -236.49% | -139.16% |
| Employees | 10 | - |
Address
1256 Briarcliff Road, N.E. Emtech Bio Suite 500
Atlanta, GA 30306
United States - Map
+1-404-7270971 (Phone)
+1-404-7129357 (Fax)
Atlanta, GA 30306
United States - Map
+1-404-7270971 (Phone)
+1-404-7129357 (Fax)
Website links
GeoVax Labs, Inc. discussions
View all discussions »Description
GeoVax Labs, Inc. (GeoVax) is a clinical stage biotechnology company engaged in research and development activities to develop, license and commercialize the manufacture and sale of human vaccines for diseases caused by human immunodeficiency virus (HIV) and other infectious agents. The Company has licensed from Emory University certain acquired immune deficiency syndrome (AIDS) vaccine technology, which was developed in collaboration with the National Institutes of Health, and the Centers for Disease Control and Prevention.
Officers and directors
| Donald G. Hildebrand | Chairman of the Board | |
| Robert T. McNally Ph.D. | President, Chief Executive Officer, Director | |
| Mark W. Reynolds CPA | Chief Financial Officer, Corporate Secretary | |
| Harriet Latham Robinson Ph.D. | Senior Vice President - Research & Development, Director | |
| John N. Spencer Jr., CPA | Director | |
| Dean G. Kollintzas | Director | |
| Peter M. Tsolinas | Director |